MARC

LEADER 00000cam a2200000Ia 4500
001 in00002442893
005 20211202191440.0
006 m d f
007 cr an|||||||||
008 090423s2008 mdu s f000 0 eng d
035 |a (OCoLC)ocn319070753 
040 |a GPO  |c GPO  |d MvI  |d UtOrBLW 
049 |a WWW 
074 |a 0499-T-02 (online) 
086 0 |a HE 20.4802:IM 7 
245 0 0 |a Guidance for industry :  |b Q3A impurities in new drug substances. 
246 3 0 |a Q3A impurities in new drug substances 
264 1 |a Sliver Spring, MD :  |b U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research ;  |a Rockville, MD :  |b Center for Biologics Evaluation and Research,  |c [2008] 
300 |a 14 pages :  |b digital, PDF file. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
538 |a Mode of access: Internet at the FDA CBER Web site. Address as of 4/23/09: http://www.fda.gov/cber/gdlns/ichq3a.pdf ; current access is available via PURL. 
500 |a Title from PDF title page (viewed on Apr. 23, 2009). 
500 |a "ICH". 
500 |a "June 2008". 
500 |a "Revision 2". 
500 |a Electronic resource. 
650 0 |a Drug adulteration. 
650 0 |a Drugs  |x Analysis. 
650 0 |a Drug approval  |z United States. 
710 2 |a Center for Drug Evaluation and Research (U.S.) 
710 2 |a Center for Biologics Evaluation and Research (U.S.) 
711 2 |a International Conference on Harmonisation. 
856 4 0 |u https://purl.fdlp.gov/GPO/LPS111818  |t 0 
999 |a MARS 
999 f f |s a517c4b0-e9af-3b8c-8cbe-e80d64e63afe  |i 59bff92a-4476-3331-9af0-d403de654bd1  |t 0 
952 f f |a Texas A&M University  |b College Station  |c Electronic Resources  |d Available Online  |t 0  |e HE 20.4802:IM 7  |h Superintendent of Documents classification 
998 f f |a HE 20.4802:IM 7  |t 0  |l Available Online